Stock BHC BAUSCH HEALTH COMPANIES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Bausch Health Companies Inc. Toronto S.E.

Equities

BHC

CA0717341071

Market Closed - Toronto S.E.
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
11.92 CAD +1.10% Intraday chart for Bausch Health Companies Inc. -0.17% +12.14%
Apr. 25 Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes MT
Apr. 25 Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes MT

Summary

  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The company's profit outlook over the next few years is a strong asset.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • With a P/E ratio at 13.25 for the current year and 8.46 for next year, earnings multiples are highly attractive compared with competitors.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company does not generate enough profits, which is an alarming weak point.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BAUSCH HEALTH COMPANIES INC. Stock Bausch Health Companies Inc.
+12.14% 3.19B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
B+
NOVARTIS AG Stock Novartis AG
+5.46% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
A+
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BHC Stock
  4. BHC Stock
  5. Ratings Bausch Health Companies Inc.